CRT has already established an enviable reputation for the productive nature of its commercial partnerships and is proud of its past achievements, which include:

• 3 partnered cancer therapies on the market;
• 1 therapy in late stage clinical studies;
• 8 therapies in phase II/III of clinical development.

CRT has also been involved in the formation of many start-up companies, including Antisoma Research Limited, Cyclacel Limited and KuDOS Pharmaceuticals Limited.

Marketed Therapeutics

Company	Therapeutic	Indication/Application
Schering-Plough	Temozolomide (Temodar®, Temodal®)	Glioma
AstraZeneca	Tomudex	Colorectal
Pfizer	Zinecard*	Cardioprotectant for use in combination with doxorubicin

* Now off patent